Combining mutations that modulate inter-subunit interactions and proteolytic inactivation enhance the stability of factor VIIIa

Hironao Wakabayashi; Jennifer M. Wintermute; Philip J. Fay

doi:10.1160/TH13-10-0918

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2014; 112(01): 43-52
DOI: 10.1160/TH13-10-0918

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Combining mutations that modulate inter-subunit interactions and proteolytic inactivation enhance the stability of factor VIIIa

Hironao Wakabayashi

¹Department of Biochemistry and Biophysics, University of Rochester School of Medicine, Rochester, New York, USA

,

Jennifer M. Wintermute

¹Department of Biochemistry and Biophysics, University of Rochester School of Medicine, Rochester, New York, USA

,

Philip J. Fay

¹Department of Biochemistry and Biophysics, University of Rochester School of Medicine, Rochester, New York, USA

› Institutsangaben

Abstract

Summary

FVIIIa is labile due to the dissociation of A2 subunit. Previously, we introduced hydrophobic mutations at select A1/A2/A3 subunit interfaces yielding more stable FVIII(a) variants. Separately we showed that altering the sequence flanking the primary FXa cleavage site in FVIIIa (Arg336) yielded reduced rates of proteolytic inactivation of FVIIIa. In this study we prepared the FXa-cleavage resistant mutant (336(P4-P3’)562) combined with mutations of Ala108Ile, Asp519Val/ Glu665Val or Ala108Ile/Asp519Val/Glu665Val and examined the effects of these combinations relative to FVIII thermal stability, rates of FVIIIa decay and proteolytic inactivation of FVIIIa by FXa. Thermal decay rates for 336(P4-P3’)562/Ala108Ile, 336(P4-P3’)562/Asp519Val/ Glu665Val, and 336(P4-P3’)562/Ala108Ile/Asp519Val/Glu665Val variants were reduced by ∼2– to 5-fold as compared with wild-type (WT) primarily reflecting the effects of the A domain interface mutations. FVIIIa decay rates for 336(P4-P3’)562/Asp519Val/Glu665Val and 336(P4-P3’)562/Ala108Ile/Asp519Val/Glu665Val variants were reduced by ∼25 fold, indicating greater stability than the control Asp519Val/Glu665Val variant (∼14-fold). Interestingly, 336(P4-P3’)562/Asp519Val/Glu665Val and 336(P4-P3’)562/Ala108Ile/ Asp519Val/Glu665Val variants showed reduced FXa-inactivation rates compared with the 336(P4-P3’)562 control (∼4-fold), suggesting A2 subunit destabilisation is a component of proteolytic inactivation. Thrombin generation assays using the combination variants were similar to the Asp519Val/Glu665Val control. These results indicate that combining multiple gain-of-function FVIII mutations yields FVIII variants with increased stability relative to a single type of mutation.

Keywords

Factor VIII - factor VIIIa - factor Xa - protein stability - thrombin generation assay

Volltext

Referenzen

References
1 Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004; 18: 1-15.
2 Fay PJ, Haidaris PJ, Smudzin TM. Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem 1991; 266: 8957-8962.
3 Lollar P, Parker CG. pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem 1990; 265: 1688-1692.
4 Lollar P, Parker ET. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J Biol Chem 1991; 266: 12481-12486.
5 Fay PJ, Beattie TL, Regan LM. et al. Model for the factor VIIIa-dependent decay of the intrinsic factor Xase. Role of subunit dissociation and factor IXa-catalysed proteolysis. J Biol Chem 1996; 271: 6027-6032.
6 Sammond DW, Eletr ZM, Purbeck C. et al. Structure-based protocol for identifying mutations that enhance protein-protein binding affinities. J Mol Biol 2007; 371: 1392-1404.
7 Wakabayashi H, Varfaj F, Deangelis J. et al. Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface. Blood 2008; 112: 2761-2769.
8 Wakabayashi H, Griffiths AE, Fay PJ. Combining mutations of charged residues at the A2 domain interface enhances factor VIII stability over single point mutations. J Thromb Haemost 2009; 07: 438-444.
9 Wakabayashi H, Griffiths AE, Fay PJ. Increasing hydrophobicity or disulfide bridging at the factor VIII A1 and C2 domain interface enhances procofactor stability. J Biol Chem 2011; 286: 25748-25755.
10 Pipe SW, Kaufman RJ. Characterisation of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997; 94: 11851-11856.
11 Gale AJ, Pellequer JL. An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa. J Thromb Haemost 2003; 01: 1966-1971.
12 Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-512.
13 Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalysed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 1991; 266: 20139-20145.
14 Plantier JL, Rolli V, Ducasse C. et al. Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiency. J Thromb Haemost 2010; 08: 286-293.
15 Nogami K, Wakabayashi H, Schmidt K. et al. Altered interactions between the A1 and A2 subunits of factor VIIIa following cleavage of A1 subunit by factor Xa. J Biol Chem 2003; 278: 1634-1641.
16 Fay PJ, Beattie T, Huggins CF. et al. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem 1994; 269: 20522-20527.
17 Varfaj F, Wakabayashi H, Fay PJ. Residues surrounding Arg336 and Arg562 contribute to the disparate rates of proteolysis of factor VIIIa catalysed by activated protein C. J Biol Chem 2007; 282: 20264-20272.
18 DeAngelis JP, Varfaj F, Wakabayashi H. et al. The role of P4-P3’ residues flanking Arg336 in facilitating activated protein C-catalysed cleavage and inactivation of factor VIIIa. Thromb Res 2011; 128: 470-476.
19 DeAngelis JP, Wakabayashi H, Fay PJ. Sequences flanking Arg336 in factor VIIIa modulate factor Xa-catalysed cleavage rates at this site and cofactor function. J Biol Chem 2012; 287: 15409-15417.
20 Goodeve AC, Reitsma PH, McVey JH. Nomenclature of genetic variants in haemostasis. J Thromb Haemost 2011; 09: 852-855.
21 Doering C, Parker ET, Healey JF. et al. Expression and characterisation of recombinant murine factor VIII. Thromb Haemost 2002; 88: 450-458.
22 Wakabayashi H, Freas J, Zhou Q. et al. Residues 110-126 in the A1 domain of factor VIII contain a Ca2+ binding site required for cofactor activity. J Biol Chem 2004; 279: 12677-12684.
23 Wakabayashi H, Su YC, Ahmad SS. et al. A Glu113Ala Mutation within a Factor VIII Ca(2+)-Binding Site Enhances Cofactor Interactions in Factor Xase. Biochemistry 2005; 44: 10298-10304.
24 Over J. Methodology of the one-stage assay of Factor VIII (VIII:C). Scand J Haematol Suppl 1984; 41: 13-24.
25 Lollar P, Fay PJ, Fass DN. Factor VIII and factor VIIIa. Methods Enzymol 1993; 222: 128-143.
26 Wakabayashi H, Koszelak ME, Mastri M. et al. Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity. Biochemistry 2001; 40: 10293-10300.
27 Wakabayashi H, Schmidt KM, Fay PJ. Ca(2+) binding to both the heavy and light chains of factor VIII is required for cofactor activity. Biochemistry 2002; 41: 8485-8492.
28 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
29 Fay PJ, Smudzin TM. Intersubunit fluorescence energy transfer in human factor VIII. J Biol Chem 1989; 264: 14005-14010.
30 Fay PJ, Smudzin TM. Topography of the human factor VIII-von Willebrand factor complex. J Biol Chem 1990; 265: 6197-6202.
31 Varfaj F, Neuberg J, Jenkins PV. et al. Role of P1 residues Arg336 and Arg562 in the activated-Protein-C-catalysed inactivation of Factor VIIIa. Biochem J 2006; 396: 355-362.
32 Vlot AJ, Koppelman SJ, van den Berg MH. et al. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 1995; 85: 3150-3157.
33 Shen BW, Spiegel PC, Chang CH. et al. The tertiary structure and domain organisation of coagulation factor VIII. Blood 2008; 111: 1240-1247.
34 Ngo JC, Huang M, Roth DA. et al. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure 2008; 16: 597-606.
35 O’Brien LM, Huggins CF, Fay PJ. Interacting regions in the A1 and A2 subunits of factor VIIIa identified by zero-length cross-linking. Blood 1997; 90: 3943-3950.
36 Monaghan M, Wakabayashi H, Wintermute J. et al. Increasing the binding affinity between FVIIIa subunits results in higher stability and greater thrombin generation in plasma. J Thromb Haemost 2013; 11 (Suppl. 02) 210.
37 Koszelak Rosenblum ME, Schmidt K, Freas J. et al. Cofactor activities of factor VIIIa and A2 subunit following cleavage of A1 subunit at Arg336. J Biol Chem 2002; 277: 11664-11669.
38 Weiss HJ, Sussman II, Hoyer LW. Stabilisation of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand’s disease. J Clin Invest 1977; 60: 390-404.